In Vitro and in Vivo Antitumor Evaluation of Berbamine for Lung Cancer Treatment

Gemcitabine (Gem) and cisplatin (Cis) are currently being used for lung cancer treatment, but they are highly toxic in high dosages. This research aimed to develop a niosome formulation containing a low-dosage Gem and Cis (NGC), as an alternative formulation for lung cancer treatment. NGC was prepared using a very simple heating method and was further optimized by D-optimal mixture design. The optimum NGC formulation with particle size, polydispersity index (PDI), and zeta potential of 166.45 nm, 0.16, and −15.28 mV, respectively, was obtained and remained stable at 27 °C with no phase separation for up to 90 days. The aerosol output was 96.22%, which indicates its suitability as aerosolized formulation. An in vitro drug release study using the dialysis bag diffusion technique showed controlled release for both drugs up to 24 h penetration. A cytotoxicity study against normal lung (MRC5) and lung cancer (A549) cell lines was investigated. The results showed that the optimized NGC had reduced cytotoxicity effects against both MRC5 and A549 when compared with the control (Gem + Cis alone) from very toxic (IC50 < 1.56 µg/mL) to weakly toxic (IC50 280.00 µg/mL) and moderately toxic (IC50 = 46.00 µg/mL), respectively, after 72 h of treatment. These findings revealed that the optimized NGC has excellent potential and is a promising prospect in aerosolized delivery systems to treat lung cancer that warrants further investigation.

Download Full-text

Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-019-03051-6 ◽

2019 ◽

Vol 145 (12) ◽

pp. 2951-2967 ◽

Cited By ~ 5

Author(s):

Qianqian Jiang ◽

Yue Yuan ◽

Yi Gong ◽

Xinmei Luo ◽

Xiaolan Su ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Treatment ◽

Therapeutic Delivery

Download Full-text

Aptamers in Non-Small Cell Lung Cancer Treatment

Molecules ◽

10.3390/molecules25143138 ◽

2020 ◽

Vol 25 (14) ◽

pp. 3138 ◽

Cited By ~ 1

Author(s):

Irena Wieleba ◽

Kamila Wojas-Krawczyk ◽

Paweł Krawczyk

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Small Cell Lung Cancer ◽

Cancer Progression ◽

Cell Lung Cancer ◽

Small Cell ◽

Production Costs ◽

Small Cell Lung ◽

Lung Cancer Treatment

Aptamers are short, single-stranded oligonucleotides which are capable of specifically binding to single molecules and cellular structures. Aptamers are also known as “chemical antibodies”. Compared to monoclonal antibodies, they are characterized by higher reaction specificity, lower molecular weight, lower production costs, and lower variability in the production stage. Aptamer research has been extended during the past twenty years, but only Macugen® has been accepted by the Food and Drug Administration (FDA) to date, and few aptamers have been examined in clinical trials. In vitro studies with aptamers have shown that they may take part in the regulation of cancer progression, angiogenesis, and metastasis processes. In this article, we focus on the potential use of aptamers in non-small cell lung cancer treatment.

Download Full-text

Novel Frog Skin-Derived Peptide Dermaseptin-PP for Lung Cancer Treatment: In vitro/vivo Evaluation and Anti-tumor Mechanisms Study

Frontiers in Chemistry ◽

10.3389/fchem.2020.00476 ◽

2020 ◽

Vol 8 ◽

Author(s):

Ziyi Dong ◽

Haiyan Hu ◽

Xianglong Yu ◽

Li Tan ◽

Chengbang Ma ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Frog Skin ◽

Lung Cancer Treatment

Download Full-text

The Rationale for Repurposing Sildenafil for Lung Cancer Treatment

Anti-Cancer Agents in Medicinal Chemistry ◽

10.2174/1871520617666171103100959 ◽

2018 ◽

Vol 18 (3) ◽

pp. 367-374 ◽

Cited By ~ 4

Author(s):

Theodore Keats ◽

Rhonda J. Rosengren ◽

John C. Ashton

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Cancer Cells ◽

Clinical Investigation ◽

Tumour Size ◽

Chemotherapeutic Agents ◽

Metabolic Effects ◽

Clinical Effects ◽

Lung Cancer Treatment

There is now a considerable body of evidence for sildenafil possessing anticancer properties. In this article, we argue the case for testing sildenafil as a lung cancer therapy chemoadjuvant. Currently, lung cancer is a disease with insufficient treatment options, with only 20% of patients responding to systemic chemotherapy, and even incremental potential improvements should be explored. We review the literature concerning the biochemical, physiological and metabolic effects on cancer cells by sildenafil alone, and when combined with chemotherapeutic agents. Most studies have shown that sildenafil is cytotoxic to cancer cells, both as a monotherapy and as a chemoadjuvant. Sildenafil enhances cancer cell apoptosis when used as a chemoadjuvant both in vitro and in vivo. In particular, in rodent experiments sildenafil has decreased tumour size compared to chemotherapy alone. Sildenafil has also been proven as an agent to decrease drug-efflux by cancer cells and increases blood perfusion to lung tissue, which can potentially increase the dosage of chemotherapeutic agents delivered to lung cancer cells compared to healthy tissue. In addition, the proven clinical effects of sildenafil on other lung diseases suggest that it could improve other patient outcomes, such as right ventricular function and quality of life. Sildenafil may also extend the half-life of docetaxel and some small molecule inhibitors used in lung cancer treatment by acting as an inhibitor of CYP3A4. We conclude that the evidence strongly warrants clinical investigation into the use of sildenafil as an agent for the treatment of lung-cancer.

Download Full-text

CT-Based dose calculations and in vivo dosimetry for lung cancer treatment

Radiotherapy and Oncology ◽

10.1016/0167-8140(96)80488-9 ◽

1995 ◽

Vol 37 ◽

pp. S15

Author(s):

M. Essers ◽

J.H. Lanson ◽

G. Leunens ◽

T. Schnabel ◽

B.J. Mijnheer

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

In Vivo Dosimetry ◽

Dose Calculations ◽

Lung Cancer Treatment

Download Full-text

The Synergistic Anticancer Effect of Dual Drug- (Cisplatin/Epigallocatechin Gallate) Loaded Gelatin Nanoparticles for Lung Cancer Treatment

Journal of Nanomaterials ◽

10.1155/2020/9181549 ◽

2020 ◽

Vol 2020 ◽

pp. 1-15

Author(s):

Yin-Ju Chen ◽

Zhi-Weng Wang ◽

Tung-Ling Lu ◽

Clinton B. Gomez ◽

Hsu-Wei Fang ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Cancer Cells ◽

Inductively Coupled Plasma ◽

Cisplatin Resistance ◽

Epigallocatechin Gallate ◽

Gelatin Nanoparticles ◽

Lung Cancer Treatment ◽

Dual Drug

Lung cancer has the highest mortality of any cancer worldwide, and cisplatin is a first-line chemotherapeutic agent for lung cancer treatment. Unfortunately, cisplatin resistance is a common cause of therapeutic failure. The ability to overcome chemoresistance is crucial to the effective treatment of lung cancer. Recently, epigallocatechin gallate (EGCG), a type of polyphenol extracted from tea, has been shown to suppress the rapid proliferation of cancer cells, including lung cancer. We tested whether nanoparticles (NPs) carrying a dual drug load, cisplatin and EGCG, could overcome chemoresistance to cisplatin, by working together to kill lung cancer cells. Self-assembling gelatin/EGCG nanoparticles (GE) were synthesized, and cisplatin was then incorporated, to construct a dual drug nanomedicine (EGCG/cisplatin-loaded gelatin nanoparticle, named as GE-Pt NP). The particle size and zeta potential were examined by dynamic light scattering (DLS). The morphological structure of GE-Pt NPs was observed by transmission electron microscopy (TEM). In vitro testing was performed using a human lung adenocarcinoma cell line (A549). A cytotoxicity examination was performed, using a WST-8 cell proliferation assay. Intracellular cisplatin content was quantified by inductively coupled plasma mass spectrometry (ICP-MS). In conclusion, we successfully prepared GE-Pt NPs, as spherical structures, approximately 75 nm in diameter, with a positive charge (+19.83±0.25 mV). The encapsulation rate of cisplatin in GE-Pt was about 63.7%, and the EGCG loading rate was around 89%. A relatively low concentration of GE-Pt NPs (EGCG 5 μg/mL : cisplatin 2 μg/mL) exhibited significant cytotoxicity, compared to cisplatin alone. The GE-Pt NPs are freely taken up by cells via endocytosis, raising the intracellular cisplatin concentration to a therapeutic level. We consider that combination therapy of cisplatin and EGCG in nanoparticles (GE-Pt NPs) may help overcome cisplatin resistance and could effectively be used in the treatment of lung cancer.

Download Full-text

Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment

Combinatorial Chemistry & High Throughput Screening ◽

10.2174/1386207323666200325155020 ◽

2020 ◽

Vol 23 (10) ◽

pp. 1064-1079

Author(s):

Ahmet Alper Öztürk ◽

İrem Namlı ◽

Kadri Güleç ◽

Şennur Görgülü

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Anticancer Activity ◽

Cell Line ◽

Anticancer Drugs ◽

Release Kinetics ◽

Prolonged Release ◽

Lung Cancer Treatment ◽

Anticancer Properties ◽

Ft Ir

Aims: To prepare lamivudine (LAM)-loaded-nanoparticles (NPs) that can be used in lung cancer treatment. To change the antiviral indication of LAM to anticancer. Background: The development of anticancer drugs is a difficult process. One approach to accelerate the availability of drugs is to reclassify drugs approved for other conditions as anticancer. The most common route of administration of anticancer drugs is intravenous injection. Oral administration of anticancer drugs may considerably change current treatment modalities of chemotherapy and improve the life quality of cancer patients. There is also a potentially significant economic advantage. Objective: To characterize the LAM-loaded-NPs and examine the anticancer activity. Methods: LAM-loaded-NPs were prepared using Nano Spray-Dryer. Properties of NPs were elucidated by particle size (PS), polydispersity index (PDI), zeta potential (ZP), SEM, encapsulation efficiency (EE%), dissolution, release kinetics, DSC and FT-IR. Then, the anticancer activity of all NPs was examined. Results: The PS values of the LAM-loaded-NPs were between 373 and 486 nm. All NPs prepared have spherical structure and positive ZP. EE% was in a range of 61-79%. NPs showed prolonged release and the release kinetics fitted to the Weibull model. NPs structures were clarified by DSC and FT-IR analysis. The results showed that the properties of NPs were directly related to the drug:polymer ratio of feed solution. NPs have potential anticancer properties against A549 cell line at low concentrations and non-toxic to CCD 19-Lu cell line. Conclusion: NPs have potential anticancer properties against human lung adenocarcinoma cells and may induce cell death effectively and be a potent modality to treat this type of cancer. These experiments also indicate that our formulations are non-toxic to normal cells. It is clear that this study would bring a new perspective to cancer therapy.

Download Full-text